Unknown

Dataset Information

0

Cyclocreatine treatment ameliorates the cognitive, autistic and epileptic phenotype in a mouse model of Creatine Transporter Deficiency.

ABSTRACT: Creatine Transporter Deficiency (CTD) is an inborn error of metabolism presenting with intellectual disability, behavioral disturbances and epilepsy. There is currently no cure for this disorder. Here, we employed novel biomarkers for monitoring brain function, together with well-established behavioral readouts for CTD mice, to longitudinally study the therapeutic efficacy of cyclocreatine (cCr) at the preclinical level. Our results show that cCr treatment is able to partially correct hemodynamic responses and EEG abnormalities, improve cognitive deficits, revert autistic-like behaviors and protect against seizures. This study provides encouraging data to support the potential therapeutic benefit of cyclocreatine or other chemically modified lipophilic analogs of Cr.

SUBMITTER: Cacciante F 

PROVIDER: S-EPMC7591530 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Cyclocreatine treatment ameliorates the cognitive, autistic and epileptic phenotype in a mouse model of Creatine Transporter Deficiency.

Cacciante Francesco F   Gennaro Mariangela M   Sagona Giulia G   Mazziotti Raffaele R   Lupori Leonardo L   Cerri Elisa E   Putignano Elena E   Butt Mark M   Do Minh-Ha T MT   McKew John C JC   Alessandrì Maria Grazia MG   Battini Roberta R   Cioni Giovanni G   Pizzorusso Tommaso T   Baroncelli Laura L  

Scientific reports 20201027 1

Creatine Transporter Deficiency (CTD) is an inborn error of metabolism presenting with intellectual disability, behavioral disturbances and epilepsy. There is currently no cure for this disorder. Here, we employed novel biomarkers for monitoring brain function, together with well-established behavioral readouts for CTD mice, to longitudinally study the therapeutic efficacy of cyclocreatine (cCr) at the preclinical level. Our results show that cCr treatment is able to partially correct hemodynami  ...[more]

Similar Datasets

Unknown Cyclocreatine treatment improves cognition in mice with creatine transporter deficiency.
| S-EPMC3408730 | biostudies-literature
Unknown Phosphocyclocreatine is the dominant form of cyclocreatine in control and creatine transporter deficiency patient fibroblasts.
| S-EPMC6924099 | biostudies-literature
Unknown A novel mouse model of creatine transporter deficiency.
| S-EPMC4243761 | biostudies-literature
Unknown Oxidative phosphorylation in creatine transporter deficiency.
| S-EPMC7722185 | biostudies-literature
Unknown X-linked creatine-transporter gene (SLC6A8) defect: a new creatine-deficiency syndrome.
| S-EPMC1226136 | biostudies-literature
Unknown Creatine transporter deficiency: Novel mutations and functional studies.
| S-EPMC4932609 | biostudies-literature
Unknown A mouse model of ATRX deficiency with cognitive deficits and autistic traits.
| S-EPMC10644498 | biostudies-literature
Unknown Dodecyl creatine ester-loaded nanoemulsion as a promising therapy for creatine transporter deficiency.
| S-EPMC6613044 | biostudies-literature
Unknown Novel translational phenotypes and biomarkers for creatine transporter deficiency.
| S-EPMC7472907 | biostudies-literature
Unknown Treatment efficacy of high-dose creatine supplementation in a child with creatine transporter (SLC6A8) deficiency.
| S-EPMC8123749 | biostudies-literature